葡萄膜黑色素瘤临床特征及基线肿瘤大小与基因表达谱状态的关系:多中心研究
该回顾性多中心研究纳入美国九家眼肿瘤中心379例接受I-125敷贴放疗并同期肿瘤活检行基因表达谱检测的葡萄膜黑色素瘤患者,分析基因表达谱亚类与临床特征的关系,发现Class 2与更大肿瘤尺寸类别相关:小肿瘤6%、中等肿瘤32%、大肿瘤53%为Class 2。
要点
- Class 2肿瘤较大尺寸类别占比更高:小肿瘤6%、中等肿瘤32%、大肿瘤53%为Class 2。
- Class 2较Class 1b与患者年龄增长(P<0.001)、更大肿瘤高度(P=0.010)等相关。
- Class 1a与Class 1b唯一显著临床差异为Class 1a患者诊断时年龄更大(P=0.034)。
核心结论
- 在多中心背景下,Class 1a与Class 1b肿瘤之间唯一显著的临床特征差异是Class 1a肿瘤患者诊断时年龄更大。
- Class 1a和Class 1b具有区别于Class 2肿瘤的临床特征。
- 基因表达谱亚类在各尺寸组间的分布与已报道的相同尺寸分组间至转移时间数据相似。
- 作者的临床发现支持先前报道的葡萄膜黑色素瘤基于分子分类的生存数据。
研究设计与样本
- 回顾性多中心研究,纳入美国九家主要眼肿瘤中心的患者。
- eligible患者为葡萄膜黑色素瘤,在2010年1月1日至2014年10月28日期间接受I-125敷贴放疗并同期肿瘤活检行基因表达谱检测。
- 收集患者人口学、基线肿瘤临床特征和基因表达谱结果数据。
- 统计分析采用Fisher精确检验、Wilcoxon秩和检验、Kruskal-Wallis检验和比例优势累积logit模型。
- 纳入标准满足者共379例患者。
主要发现
- 基因表达谱分类将队列分为两个主要组:Class 1(n=263)和Class 2(n=113)。
- Class 1肿瘤进一步分为Class 1a(n=186)和Class 1b(n=77)。
- Class 1与Class 2肿瘤之间的差异与既往研究相似,但发现Class 2肿瘤更可能伴有渗出性视网膜脱离(P<0.001)。
- Class 1与Class 2肿瘤在脂褐素、玻璃膜疣或视网膜下液存在方面无统计学显著差异。
- Class 1a肿瘤患者与Class 1b相比显著更年长(P=0.034)。
关键数值与推荐
- 基因表达谱分类:Class 1(n=263)和Class 2(n=113);Class 1进一步分为Class 1a(n=186)和Class 1b(n=77)。
- Class 2与Class 1b比较:年龄增长P<0.001、更大肿瘤高度P=0.010、睫状体受累P=0.001、渗出性视网膜脱离P=0.024、前部肿瘤位置P<0.001。
- Class 1a与Class 1b比较:Class 1a患者显著更年长(P=0.034)。
- 按Collaborative Ocular Melanoma Study尺寸类别:小肿瘤6%、中等肿瘤32%、大肿瘤53%为Class 2。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To study the relationship between gene expression profile subclass and clinical features in a multicenter cohort of patients with uveal melanoma. METHODS: A retrospective, multicenter study was undertaken with patients entered from nine major ocular oncology centers from across the United States. Eligible patients had uveal melanoma and underwent I-125 plaque brachytherapy with concurrent tumor biopsy with gene expression profile testing between January 1, 2010, and October 28, 2014. Data were collected regarding patient demographics, baseline tumor clinical features, and gene expression profile results. Statistical analyses were performed using the Fisher's exact test, Wilcoxon rank-sum test, Kruskal-Wallis test, and proportional-odds cumulative logit modeling. RESULTS: Inclusion criteria were met for 379 patients. Gene expression profile class divided the cohort into two main groups, Class 1 (n = 263) and Class 2 (n = 113). Class 1 tumors were further subdivided into Class 1a (n = 186) and Class 1b (n = 77). The differences between Class 1 and Class 2 tumors were similar to previous studies, except the finding of Class 2 tumors being more likely to have associated exudative retinal detachment (P < 0.001). There was no statistically significant difference between Class 1 and Class 2 tumors based on the presence of lipofuscin, drusen, or subretinal fluid. Class 1a tumor patients, compared with Class 1b, were significantly older (P = 0.034). Class 2 tumors, when compared with Class 1b, were associated with increasing patient age (P < 0.001), larger tumor height (P = 0.010), ciliary body involvement (P = 0.001), exudative retinal detachment (P = 0.024), and anterior tumor location (P < 0.001). When the tumors were grouped into Collaborative Ocular Melanoma Study size categories, increasing tumor size category was significantly associated with Class 2 status: 6% of small tumors, 32% of medium tumors, and 53% of large tumors were Class 2. CONCLUSION: In a multi-institutional setting, we found that the only significant difference in clinical features between Class 1a and Class 1b tumors was that patients with Class 1a tumors were older at the time of diagnosis. We also found that Class 1a and Class 1b have clinical features distinct from Class 2 tumors. The distribution of the gene expression profile subclasses among the size groups was similar to reported time-to-metastasis data among the same size groupings. Our clinical findings support the current molecular classification-based survival data previously reported in uveal melanoma.
引用
- Berry D, Seider M, Stinnett S, et al. RELATIONSHIP OF CLINICAL FEATURES AND BASELINE TUMOR SIZE WITH GENE EXPRESSION PROFILE STATUS IN UVEAL MELANOMA: A Multi-institutional Study. Retina. 2019. PMID: 29578940. doi:10.1097/IAE.0000000000002113
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。